Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C

• Carolina Pizarro ^[1] ; Mauricio Venegas ^[1] ; Karen Hola ^[2] ; Gladys Smok ^[1] ; Javier Brahm ^[1]
  1. [1] Universidad de Chile

     Universidad de Chile

     Santiago, Chile

     
  2. [2] Hospital Naval Almirante Nef

     Hospital Naval Almirante Nef

     Viña del Mar, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 139, Nº. 6, 2011, págs. 704-709
• Idioma: español
• Títulos paralelos:
  • Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C
• Enlaces
  • Texto completo
• Resumen

  • Background: The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response. Aim: To report our experience in the treatment of chronic hepatitis C. Material and Methods: Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day. Results: Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4% of patients, respectively. Twenty four patients (46 %), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment. Conclusions: Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.